About the Program

Explore the role of CDK4/6 inhibitors in early breast cancer treatment, from patient selection to managing side effects and disease progression. Join top oncology experts, challenge perspectives, and help shape the future of breast cancer care!

Program Learning Objectives

• Use the latest screening guidelines to assess risk features of disease recurrence in patients with eBC (e.g., biomarkers, lymph node involvement)
• Discuss the effectiveness of CDK4/6 inhibitor therapy in the context of the latest clinical trial and real-world evidence, and formulate individual treatment plans
• Compare strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors within the Canadian healthcare system

Privacy Statement and Terms & Conditions